Fig. 5.

HDAC6 inhibition prevents platelet tubulin deacetylation. A and B: purified human platelets were pretreated with the pan-HDAC inhibitor TSA (10 μM), the HDAC6-specific inhibitor tubacin (10 μM), the HDAC1/3 inhibitor TC-H 106 (10 μM), or vehicle alone (DMSO) (A) or the SIRT1 inhibitor EX 527 (10 μM), the SIRT2 inhibitor AGK2 (10 μM), or vehicle alone (DMSO) (B) before stimulation with 1 μg/ml CRP (2–10 min). Platelets were lysed into sample buffer and analyzed for tubulin acetylation by Western blot. C and D: purified human platelets were pretreated with the pan-HDAC inhibitor TSA (10 μM), the HDAC6-specific inhibitor tubacin (10 μM), or vehicle alone (DMSO) before stimulation (2–10 min) with the PAR1 agonist peptide TRAP6 (C) or the PAR4 agonist peptide GYPGKF (D). Western blot results are each representative of 4 experiments.